Clinical Trials on Autosomal Dominant Polycystic Kidney Disease (ADPKD

Total 229 results

University of North Carolina, Chapel Hill
National Institute of General Medical Sciences (NIGMS)

Completed

ADPKD Alterations in Hepatic Transporter Function

Renal Disease | Autosomal Dominant Polycystic Kidney Disease | ADPKD

United States
Kadmon Corporation, LLC

Terminated

Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Assistance Publique - Hôpitaux de Paris
IPSEN pharmaceutical company, Boulogne-Billancourt, France

Completed

Lanreotide In Polycystic Kidney Disease Study (LIPS)

Autosomal Dominant Polycystic Kidney Disease (ADPKD

France
University Medical Center Groningen
Radboud University Medical Center; Erasmus Medical Center; Leiden University...

Unknown

Study of Lanreotide to Treat Polycystic Kidney Disease (DIPAK1)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Netherlands
Mario Negri Institute for Pharmacological Research

Completed

Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study (ALADIN)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Italy
Children's National Research Institute

Recruiting

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study (ADPKD)

ADPKD

United States
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT)

ADPKD | Polycystic Kidney Disease, Adult

United States
Tufts Medical Center

Completed

Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Autosomal Dominant Polycystic Kidney Disease (ADPKD)
University of Cologne

Recruiting

The German ADPKD Tolvaptan Treatment Registry (AD(H)PKD)

ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Germany
University of Zurich

Completed

Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Switzerland
University of Colorado, Denver
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

ADPKD

United States
Rigshospitalet, Denmark
Aarhus University Hospital

Completed

Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease

ADPKD

Denmark
Azienda Ospedaliero-Universitaria Consorziale Policlinico...

Unknown

Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease (METROPOLIS)

ADPKD

Italy
University of Cologne

Completed

Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Keto-ADPKD)

ADPKD

Germany
Otsuka Pharmaceutical Development & Commercialization...
Otsuka Pharmaceutical Co., Ltd.

Completed

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease (OVERTURE)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Argentina, Australia, Belgium, Brazil, Canada, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Mario Negri Institute for Pharmacological Research

Terminated

Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency (SIRENA-II)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Italy
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease (ESSENTIAL)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Korea, Republic of
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
Shanghai Changzheng Hospital

Unknown

Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

China
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Otsuka Canada Pharmaceutical Inc.

Recruiting

Canadian Medical Assessment of JINARC™ Outcomes Registry (C-MAJOR)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Canada
University Hospital, Brest

Completed

Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD (GeneQuest)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

France
Esther Meijer

Unknown

Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt (WATER)

Polycystic Kidney, Autosomal Dominant | Autosomal Dominant Polycystic Kidney | ADPKD

Netherlands
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ACTION)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, Hungary, United Kingdom, Australia, Bulgaria, Poland, Turkey
University of Colorado, Denver

Active, not recruiting

Statin Therapy in Patients With Early Stage ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Kadmon, a Sanofi Company

Completed

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Universitair Ziekenhuis Brussel

Not yet recruiting

Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? (ADKETONE)

ADPKD
Regulus Therapeutics Inc.

Recruiting

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant | Autosomal Dominant Polycystic Kidney Disease | ADPKD

United States
University of California, San Francisco

Recruiting

Genetic Testing in Autosomal Dominant Polycystic Kidney Disease

ADPKD

United States
Rege Nephro Co., Ltd.

Recruiting

Study of Tamibarotene in Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Japan
Emory University
PKD Foundation

Completed

ADPKD Cohort Study

Autosomal Dominant Polycystic Kidney Disease

United States
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Intrarenal Microvasculature in ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Mario Negri Institute for Pharmacological Research
Otsuka Pharmaceutical Italy S.r.l.

Completed

Tolvaptan-Octreotide LAR Combination in ADPKD (TOOL)

Autosomal Dominant Polycystic Kidney Disease

Italy
Mayo Clinic
University of Kansas Medical Center

Completed

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
CHU de Reims

Completed

ADPKD and Peritoneal Dialysis: How Anticipate Peritoneal Pressure? (PDP-ADPKD)

Autosomal Dominant Polycystic Kidney Disease

France
Otsuka Pharmaceutical Development & Commercialization...

Completed

Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney Disease

United States
Regional Hospital Holstebro
Aarhus University Hospital

Completed

Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TOPO)

Autosomal Dominant Polycystic Kidney Disease

Denmark
University Hospital, Brest

Unknown

Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease) (GENKYST)

Autosomal Dominant Polycystic Kidney Disease

France
Federico II University

Completed

Effects of Somatostatin on Liver in ADPKD

Autosomal Dominant Polycystic Kidney Disease
Kyorin University

Unknown

Efficacy of Tolvaptan on ADPKD Patients

Autosomal Dominant Polycystic Kidney Disease

Japan
Cambridge University Hospitals NHS Foundation Trust
Addenbrookes Charitable Trust; PKD Charity; British Renal Society & British Kidney...

Completed

High Water Intake in Polycystic Kidney Disease (DRINK)

Autosomal Dominant Polycystic Kidney Disease

United Kingdom
University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...

Completed

Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP II)

Autosomal Dominant Polycystic Kidney Disease

United States
Andreas L. Serra

Unknown

The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe

Autosomal Dominant Polycystic Kidney Disease

France, Switzerland, Germany, Netherlands, Belgium, Czech Republic, Italy, Spain, Turkey, United Kingdom
Reata, a wholly owned subsidiary of Biogen

Terminated

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, United Kingdom, Australia, France, Japan, Germany, Belgium, Czechia, Italy
Otsuka Pharmaceutical Europe Ltd

Unknown

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe (ACQUIRE)

Autosomal Dominant Polycystic Kidney Disease

Spain, United Kingdom, Germany, France, Belgium, Switzerland, Austria
Federico II University

Completed

Effects of Somatostatin on ADPKD Heart

Autosomal Dominant Polycystic Kidney Disease | Glomerular Filtration Rate > 40 ml/Min
CHU de Reims

Completed

Outcome of Autosomal Dominant Polycystic Kidney Disease Patients on Peritoneal Dialysis: a National Retrospective Study Based on Two French Registries (the French Language Peritoneal Dialysis Registry and the French Renal Epidemiology and Information Network). (ADPKDPD)

Polycystic Kidney Diseases

France
The University of Queensland

Recruiting

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Autosomal Dominant Polycystic Kidney Disease

Australia

Clinical Trials on Autosomal Dominant Polycystic Kidney Disease (ADPKD

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations